Roche and Oryzon announce collaboration to develop epigenetics-based medicines
Collaboration spans research, development and commercialization of LSD1 inhibitors for oncology, haematology and non-malignant conditions
Lead agent ORY-1001 currently in phase I/IIa study in AML
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Oryzon Genomics SA today announced they have entered into a worldwide collaboration to research, develop and commercialize inhibitors of Lysine Specific Demethylase-1 (LSD1; KDM1A), an epigenetic modulator that regulates gene expression.
